Sign up online today & collaborate
or click here to find out more
AstraZeneca and Isis Pharmaceuticals will collaborate to develop antisense therapies for cardiovascular, metabolic and renal diseases.
Antisense drugs are short, chemically-modified, single-stranded nucleic acids that have the ability to target any gene product. They can act inside the cell to target RNA and prevent the production of disease-causing proteins, increase the production of proteins deficient in disease, or target toxic RNAs that are unable to generate proteins.
Under the terms of the deal, AZ will pay $65 million to Isis upfront. Isis will also be eligible for milestone payments and tiered royalties on annual net sales.
The two companies have previously teamed up to investigate RNA therapeutics for cancer.
For m ore click here